Abstract
This Practice Point commentary discusses a computer-based decision analysis by Huang et al. that assessed the effect of comorbid illnesses and functional status on the benefits of intensive glycemic control (HbA1c 7.0%) in hypothetical older patients with type 2 diabetes mellitus (T2DM). The expected benefits of intensive glycemic control ranged from 51–116 additional days of quality-adjusted life expectancy (quality-adjusted days). Expected benefits decreased with increasing age or number of comorbidities, and increased with duration of T2DM. We highlight the issues to consider in the extrapolation of theoretical models to the clinical setting. In the examined study, the input data were several decades old, interpretation of the mean quality-adjusted days gained lacked comparative benchmarks, and a 'survivor effect' probably accounted for the increased benefit associated with an increased duration of T2DM. Nevertheless, the data do suggest that the benefits of intensive control might be diminished in older patients with multiple comorbidities and functional impairments.
References
Huang ES et al. (2008) The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 149: 11–19
Eastman RC et al. (1997) Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care 20: 725–734
Klein R and Moss S (1995) A comparison of the study populations in the Diabetes Control and Complications Trial and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Arch Intern Med 155: 745–754
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853
Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545–2559
American Diabetes Association et al. (2008) Standards of medical care in diabetes—2008. Diabetes Care 31 (Suppl 1): S12–S54
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Christopher D Saudek declared associations with the following companies: GlaxoSmithKline, Novartis and Pfizer (reports consulting or medical advisory board participation). Rita R Kalyani declared no competing interests.
Rights and permissions
About this article
Cite this article
Saudek, C., Kalyani, R. Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus?. Nat Rev Endocrinol 5, 78–79 (2009). https://doi.org/10.1038/ncpendmet1041
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet1041
- Springer Nature Limited